220 related articles for article (PubMed ID: 20805496)
1. Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells.
Naramura M; Nandwani N; Gu H; Band V; Band H
Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16274-9. PubMed ID: 20805496
[TBL] [Abstract][Full Text] [Related]
2. A novel CBL-Bflox/flox mouse model allows tissue-selective fully conditional CBL/CBL-B double-knockout: CD4-Cre mediated CBL/CBL-B deletion occurs in both T-cells and hematopoietic stem cells.
Goetz B; An W; Mohapatra B; Zutshi N; Iseka F; Storck MD; Meza J; Sheinin Y; Band V; Band H
Oncotarget; 2016 Aug; 7(32):51107-51123. PubMed ID: 27276677
[TBL] [Abstract][Full Text] [Related]
3. VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease.
An W; Mohapatra BC; Zutshi N; Bielecki TA; Goez BT; Luan H; Iseka F; Mushtaq I; Storck MD; Band V; Band H
Oncotarget; 2016 Sep; 7(37):59006-59016. PubMed ID: 27449297
[TBL] [Abstract][Full Text] [Related]
4. Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders.
William BM; An W; Feng D; Nadeau S; Mohapatra BC; Storck MA; Band V; Band H
Hematology; 2016 May; 21(4):218-24. PubMed ID: 26177294
[TBL] [Abstract][Full Text] [Related]
5. Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy.
An W; Nadeau SA; Mohapatra BC; Feng D; Zutshi N; Storck MD; Arya P; Talmadge JE; Meza JL; Band V; Band H
Oncotarget; 2015 Apr; 6(12):10498-509. PubMed ID: 25871390
[TBL] [Abstract][Full Text] [Related]
6. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
[TBL] [Abstract][Full Text] [Related]
7. An essential role of CBL and CBL-B ubiquitin ligases in mammary stem cell maintenance.
Mohapatra B; Zutshi N; An W; Goetz B; Arya P; Bielecki TA; Mushtaq I; Storck MD; Meza JL; Band V; Band H
Development; 2017 Mar; 144(6):1072-1086. PubMed ID: 28100467
[TBL] [Abstract][Full Text] [Related]
8. Negative regulation of CD40-mediated B cell responses by E3 ubiquitin ligase Casitas-B-lineage lymphoma protein-B.
Qiao G; Lei M; Li Z; Sun Y; Minto A; Fu YX; Ying H; Quigg RJ; Zhang J
J Immunol; 2007 Oct; 179(7):4473-9. PubMed ID: 17878343
[TBL] [Abstract][Full Text] [Related]
9. The E3 ubiquitin ligase c-Cbl restricts development and functions of hematopoietic stem cells.
Rathinam C; Thien CB; Langdon WY; Gu H; Flavell RA
Genes Dev; 2008 Apr; 22(8):992-7. PubMed ID: 18413713
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.
Duyvestyn JM; Taylor SJ; Dagger SA; Orandle M; Morse HC; Thien CB; Langdon WY
PLoS One; 2014; 9(4):e94717. PubMed ID: 24718698
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.
Loeser S; Loser K; Bijker MS; Rangachari M; van der Burg SH; Wada T; Beissert S; Melief CJ; Penninger JM
J Exp Med; 2007 Apr; 204(4):879-91. PubMed ID: 17403934
[TBL] [Abstract][Full Text] [Related]
12. Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders.
Naramura M; Nadeau S; Mohapatra B; Ahmad G; Mukhopadhyay C; Sattler M; Raja SM; Natarajan A; Band V; Band H
Oncotarget; 2011 Mar; 2(3):245-50. PubMed ID: 21422499
[TBL] [Abstract][Full Text] [Related]
13. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.
Paolino M; Choidas A; Wallner S; Pranjic B; Uribesalgo I; Loeser S; Jamieson AM; Langdon WY; Ikeda F; Fededa JP; Cronin SJ; Nitsch R; Schultz-Fademrecht C; Eickhoff J; Menninger S; Unger A; Torka R; Gruber T; Hinterleitner R; Baier G; Wolf D; Ullrich A; Klebl BM; Penninger JM
Nature; 2014 Mar; 507(7493):508-12. PubMed ID: 24553136
[TBL] [Abstract][Full Text] [Related]
14. Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b.
Kitaura Y; Jang IK; Wang Y; Han YC; Inazu T; Cadera EJ; Schlissel M; Hardy RR; Gu H
Immunity; 2007 May; 26(5):567-78. PubMed ID: 17493844
[TBL] [Abstract][Full Text] [Related]
15. T-cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b.
Qiao G; Li Z; Molinero L; Alegre ML; Ying H; Sun Z; Penninger JM; Zhang J
Mol Cell Biol; 2008 Apr; 28(7):2470-80. PubMed ID: 18227156
[TBL] [Abstract][Full Text] [Related]
16. Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions.
Paolino M; Thien CB; Gruber T; Hinterleitner R; Baier G; Langdon WY; Penninger JM
J Immunol; 2011 Feb; 186(4):2138-47. PubMed ID: 21248250
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitin Ligases CBL and CBL-B Maintain the Homeostasis and Immune Quiescence of Dendritic Cells.
Tong H; Li X; Zhang J; Gong L; Sun W; Calderon V; Zhang X; Li Y; Gadzinski A; Langdon WY; Reizis B; Zou Y; Gu H
Front Immunol; 2021; 12():757231. PubMed ID: 34630435
[TBL] [Abstract][Full Text] [Related]
18. Cbl-family ubiquitin ligases and their recruitment of CIN85 are largely dispensable for epidermal growth factor receptor endocytosis.
Ahmad G; Mohapatra BC; Schulte NA; Nadeau SA; Luan H; Zutshi N; Tom E; Ortega-Cava C; Tu C; Sanada M; Ogawa S; Toews ML; Band V; Band H
Int J Biochem Cell Biol; 2014 Dec; 57():123-34. PubMed ID: 25449262
[TBL] [Abstract][Full Text] [Related]
19. T cell activation threshold regulated by E3 ubiquitin ligase Cbl-b determines fate of inducible regulatory T cells.
Qiao G; Zhao Y; Li Z; Tang PQ; Langdon WY; Yang T; Zhang J
J Immunol; 2013 Jul; 191(2):632-9. PubMed ID: 23749633
[TBL] [Abstract][Full Text] [Related]
20. E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis.
Ahmed SF; Buetow L; Gabrielsen M; Lilla S; Sibbet GJ; Sumpton D; Zanivan S; Hedley A; Clark W; Huang DT
Oncogene; 2021 Mar; 40(12):2149-2164. PubMed ID: 33627783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
